| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter.
|
Nature
|
2009
|
5.34
|
|
2
|
Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo.
|
Immunity
|
2002
|
4.15
|
|
3
|
Of lineage and legacy: the development of mammalian hematopoietic stem cells.
|
Nat Immunol
|
2008
|
4.04
|
|
4
|
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.
|
Blood
|
2005
|
3.32
|
|
5
|
DNA specificity determinants associate with distinct transcription factor functions.
|
PLoS Genet
|
2009
|
2.56
|
|
6
|
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
|
Nat Genet
|
2007
|
2.18
|
|
7
|
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
|
Cancer Cell
|
2006
|
2.09
|
|
8
|
Core-binding factors in hematopoiesis and immune function.
|
Oncogene
|
2004
|
2.04
|
|
9
|
The allantois and chorion, when isolated before circulation or chorio-allantoic fusion, have hematopoietic potential.
|
Development
|
2006
|
1.88
|
|
10
|
Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells.
|
Cell Stem Cell
|
2011
|
1.76
|
|
11
|
CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
|
Blood
|
2009
|
1.74
|
|
12
|
Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification.
|
Blood
|
2008
|
1.67
|
|
13
|
Whole-mount three-dimensional imaging of internally localized immunostained cells within mouse embryos.
|
Nat Protoc
|
2012
|
1.58
|
|
14
|
Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells.
|
Proc Natl Acad Sci U S A
|
2012
|
1.54
|
|
15
|
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
|
Blood
|
2013
|
1.46
|
|
16
|
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.
|
EMBO J
|
2007
|
1.44
|
|
17
|
Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta.
|
Chem Biol
|
2007
|
1.44
|
|
18
|
Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.
|
Cancer Cell
|
2007
|
1.43
|
|
19
|
The core-binding factor beta subunit is required for bone formation and hematopoietic maturation.
|
Nat Genet
|
2002
|
1.36
|
|
20
|
The expression of Sox17 identifies and regulates haemogenic endothelium.
|
Nat Cell Biol
|
2013
|
1.28
|
|
21
|
Leukemia and hematopoietic stem cells: balancing proliferation and quiescence.
|
Cell Cycle
|
2008
|
1.28
|
|
22
|
Runx1 function in hematopoiesis is required in cells that express Tek.
|
Blood
|
2005
|
1.25
|
|
23
|
Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
|
Blood
|
2012
|
1.22
|
|
24
|
Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating myeloid and lymphoid cells, but not in maturing erythroid cells.
|
Stem Cells
|
2004
|
1.21
|
|
25
|
RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
|
Crit Rev Oncog
|
2011
|
1.15
|
|
26
|
Endothelio-mesenchymal interaction controls runx1 expression and modulates the notch pathway to initiate aortic hematopoiesis.
|
Dev Cell
|
2013
|
1.13
|
|
27
|
Energetic contribution of residues in the Runx1 Runt domain to DNA binding.
|
J Biol Chem
|
2003
|
1.12
|
|
28
|
T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage.
|
Blood
|
2006
|
1.11
|
|
29
|
Hematopoietic stem cell emergence in the conceptus and the role of Runx1.
|
Int J Dev Biol
|
2010
|
1.11
|
|
30
|
CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium.
|
Nat Struct Mol Biol
|
2004
|
1.08
|
|
31
|
Runx1 loss minimally impacts long-term hematopoietic stem cells.
|
PLoS One
|
2011
|
1.06
|
|
32
|
Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells.
|
Development
|
2013
|
1.05
|
|
33
|
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
|
Blood
|
2005
|
1.04
|
|
34
|
Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model.
|
Blood
|
2010
|
1.02
|
|
35
|
Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
|
Blood
|
2009
|
0.98
|
|
36
|
Possible roles of Runx1 and Sox9 in incipient intramembranous ossification.
|
J Bone Miner Res
|
2004
|
0.96
|
|
37
|
Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.
|
Nat Struct Biol
|
2002
|
0.92
|
|
38
|
Runx1 dose-dependently regulates endochondral ossification during skeletal development and fracture healing.
|
J Bone Miner Res
|
2012
|
0.91
|
|
39
|
Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit.
|
J Biol Chem
|
2003
|
0.90
|
|
40
|
Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC.
|
Blood Cells Mol Dis
|
2003
|
0.85
|
|
41
|
Runx1 and Cbfβ regulate the development of Flt3+ dendritic cell progenitors and restrict myeloproliferative disorder.
|
Blood
|
2014
|
0.84
|
|
42
|
The role of CBFbeta in AML1-ETO's activity.
|
Blood
|
2009
|
0.84
|
|
43
|
Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
|
J Mol Biol
|
2010
|
0.83
|
|
44
|
Visualizing blood cell emergence from aortic endothelium.
|
Cell Stem Cell
|
2010
|
0.82
|
|
45
|
A MENage à Trois in leukemia.
|
Cancer Cell
|
2008
|
0.81
|
|
46
|
A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation.
|
J Mol Biol
|
2006
|
0.81
|
|
47
|
Tyrosyl phosphorylation toggles a Runx1 switch.
|
Genes Dev
|
2012
|
0.78
|